Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.76
BRKR's Cash to Debt is ranked lower than
57% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. BRKR: 1.76 )
Ranked among companies with meaningful Cash to Debt only.
BRKR' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 1.43 Max: N/A
Current: 1.76
Equity to Asset 0.42
BRKR's Equity to Asset is ranked lower than
73% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BRKR: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
BRKR' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.43 Max: 0.69
Current: 0.42
0.14
0.69
Interest Coverage 10.95
BRKR's Interest Coverage is ranked lower than
99.99% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. BRKR: 10.95 )
Ranked among companies with meaningful Interest Coverage only.
BRKR' s Interest Coverage Range Over the Past 10 Years
Min: 7.92  Med: 12.63 Max: 59.87
Current: 10.95
7.92
59.87
F-Score: 7
Z-Score: 3.74
M-Score: -2.80
WACC vs ROIC
7.98%
19.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 8.97
BRKR's Operating margin (%) is ranked higher than
68% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. BRKR: 8.97 )
Ranked among companies with meaningful Operating margin (%) only.
BRKR' s Operating margin (%) Range Over the Past 10 Years
Min: 5.83  Med: 9.07 Max: 13.34
Current: 8.97
5.83
13.34
Net-margin (%) 6.26
BRKR's Net-margin (%) is ranked higher than
63% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. BRKR: 6.26 )
Ranked among companies with meaningful Net-margin (%) only.
BRKR' s Net-margin (%) Range Over the Past 10 Years
Min: 2.62  Med: 4.97 Max: 9.58
Current: 6.26
2.62
9.58
ROE (%) 13.60
BRKR's ROE (%) is ranked higher than
68% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. BRKR: 13.60 )
Ranked among companies with meaningful ROE (%) only.
BRKR' s ROE (%) Range Over the Past 10 Years
Min: 4.36  Med: 12.69 Max: 23.93
Current: 13.6
4.36
23.93
ROA (%) 5.62
BRKR's ROA (%) is ranked higher than
65% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. BRKR: 5.62 )
Ranked among companies with meaningful ROA (%) only.
BRKR' s ROA (%) Range Over the Past 10 Years
Min: 2.45  Med: 4.85 Max: 11.34
Current: 5.62
2.45
11.34
ROC (Joel Greenblatt) (%) 28.19
BRKR's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. BRKR: 28.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BRKR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 14.24  Med: 27.20 Max: 54.93
Current: 28.19
14.24
54.93
Revenue Growth (3Y)(%) 2.50
BRKR's Revenue Growth (3Y)(%) is ranked lower than
61% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. BRKR: 2.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BRKR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 16.60 Max: 22.8
Current: 2.5
0
22.8
EBITDA Growth (3Y)(%) -5.70
BRKR's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. BRKR: -5.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BRKR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.40 Max: 153.7
Current: -5.7
0
153.7
EPS Growth (3Y)(%) -15.40
BRKR's EPS Growth (3Y)(%) is ranked lower than
70% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. BRKR: -15.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BRKR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -2.00 Max: 59.8
Current: -15.4
0
59.8
» BRKR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

BRKR Guru Trades in Q1 2015

Steven Cohen 188,200 sh (New)
Jim Simons 226,310 sh (New)
Murray Stahl 45,454 sh (+4.96%)
NWQ Managers 1,700,988 sh (+0.15%)
Vanguard Health Care Fund 4,669,258 sh (unchged)
Paul Tudor Jones Sold Out
Pioneer Investments Sold Out
Joel Greenblatt 903,808 sh (-45.10%)
» More
Q2 2015

BRKR Guru Trades in Q2 2015

Mariko Gordon 198,875 sh (New)
NWQ Managers 1,843,923 sh (+8.40%)
Vanguard Health Care Fund 4,669,258 sh (unchged)
Murray Stahl 43,955 sh (-3.30%)
Jim Simons 69,710 sh (-69.20%)
Joel Greenblatt 126,102 sh (-86.05%)
Steven Cohen 23,000 sh (-87.78%)
» More
Q3 2015

BRKR Guru Trades in Q3 2015

Ray Dalio 25,806 sh (New)
Mariko Gordon 219,866 sh (+10.55%)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
NWQ Managers 1,820,880 sh (-1.25%)
Murray Stahl 39,774 sh (-9.51%)
Vanguard Health Care Fund 3,821,158 sh (-18.16%)
» More
Q4 2015

BRKR Guru Trades in Q4 2015

Ray Dalio Sold Out
Vanguard Health Care Fund Sold Out
Mariko Gordon 195,199 sh (-11.22%)
Murray Stahl 24,926 sh (-37.33%)
NWQ Managers 631,709 sh (-65.31%)
» More
» Details

Insider Trades

Latest Guru Trades with BRKR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 60.90
BRKR's P/E(ttm) is ranked lower than
85% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.35 vs. BRKR: 60.90 )
Ranked among companies with meaningful P/E(ttm) only.
BRKR' s P/E(ttm) Range Over the Past 10 Years
Min: 7.21  Med: 34.27 Max: 427
Current: 60.9
7.21
427
Forward P/E 22.88
BRKR's Forward P/E is ranked lower than
73% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.92 vs. BRKR: 22.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 60.90
BRKR's PE(NRI) is ranked lower than
84% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. BRKR: 60.90 )
Ranked among companies with meaningful PE(NRI) only.
BRKR' s PE(NRI) Range Over the Past 10 Years
Min: 7.21  Med: 34.23 Max: 427
Current: 60.9
7.21
427
P/B 5.47
BRKR's P/B is ranked lower than
86% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. BRKR: 5.47 )
Ranked among companies with meaningful P/B only.
BRKR' s P/B Range Over the Past 10 Years
Min: 1.36  Med: 4.13 Max: 8.94
Current: 5.47
1.36
8.94
P/S 2.42
BRKR's P/S is ranked lower than
53% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. BRKR: 2.42 )
Ranked among companies with meaningful P/S only.
BRKR' s P/S Range Over the Past 10 Years
Min: 0.5  Med: 1.75 Max: 2.55
Current: 2.42
0.5
2.55
PFCF 33.45
BRKR's PFCF is ranked lower than
61% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.05 vs. BRKR: 33.45 )
Ranked among companies with meaningful PFCF only.
BRKR' s PFCF Range Over the Past 10 Years
Min: 9.23  Med: 25.97 Max: 159.85
Current: 33.45
9.23
159.85
POCF 26.99
BRKR's POCF is ranked lower than
67% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.46 vs. BRKR: 26.99 )
Ranked among companies with meaningful POCF only.
BRKR' s POCF Range Over the Past 10 Years
Min: 5.78  Med: 20.13 Max: 51.74
Current: 26.99
5.78
51.74
EV-to-EBIT 30.23
BRKR's EV-to-EBIT is ranked lower than
68% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.84 vs. BRKR: 30.23 )
Ranked among companies with meaningful EV-to-EBIT only.
BRKR' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.2  Med: 20.10 Max: 53.2
Current: 30.23
5.2
53.2
EV-to-EBITDA 21.52
BRKR's EV-to-EBITDA is ranked lower than
74% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.36 vs. BRKR: 21.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
BRKR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.7  Med: 14.70 Max: 28.7
Current: 21.52
4.7
28.7
PEG 119.80
BRKR's PEG is ranked lower than
98% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. BRKR: 119.80 )
Ranked among companies with meaningful PEG only.
BRKR' s PEG Range Over the Past 10 Years
Min: 0.01  Med: 1.31 Max: 662
Current: 119.8
0.01
662
Shiller P/E 50.05
BRKR's Shiller P/E is ranked lower than
76% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. BRKR: 50.05 )
Ranked among companies with meaningful Shiller P/E only.
BRKR' s Shiller P/E Range Over the Past 10 Years
Min: 35.08  Med: 50.20 Max: 96.73
Current: 50.05
35.08
96.73
Current Ratio 2.05
BRKR's Current Ratio is ranked lower than
58% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BRKR: 2.05 )
Ranked among companies with meaningful Current Ratio only.
BRKR' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.10 Max: 4.99
Current: 2.05
1.26
4.99
Quick Ratio 1.34
BRKR's Quick Ratio is ranked lower than
73% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BRKR: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
BRKR' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.22 Max: 3.95
Current: 1.34
0.43
3.95
Days Inventory 186.48
BRKR's Days Inventory is ranked lower than
86% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. BRKR: 186.48 )
Ranked among companies with meaningful Days Inventory only.
BRKR' s Days Inventory Range Over the Past 10 Years
Min: 186.27  Med: 216.33 Max: 264.16
Current: 186.48
186.27
264.16
Days Sales Outstanding 52.76
BRKR's Days Sales Outstanding is ranked higher than
65% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. BRKR: 52.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
BRKR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.67  Med: 61.77 Max: 66.67
Current: 52.76
56.67
66.67
Days Payable 28.75
BRKR's Days Payable is ranked lower than
69% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. BRKR: 28.75 )
Ranked among companies with meaningful Days Payable only.
BRKR' s Days Payable Range Over the Past 10 Years
Min: 26.4  Med: 30.45 Max: 147.25
Current: 28.75
26.4
147.25

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 17.21
BRKR's Price/Net Current Asset Value is ranked lower than
71% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. BRKR: 17.21 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BRKR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.41  Med: 12.11 Max: 103.75
Current: 17.21
2.41
103.75
Price/Tangible Book 8.64
BRKR's Price/Tangible Book is ranked lower than
69% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.88 vs. BRKR: 8.64 )
Ranked among companies with meaningful Price/Tangible Book only.
BRKR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.34  Med: 5.40 Max: 20.45
Current: 8.64
1.34
20.45
Price/Projected FCF 2.80
BRKR's Price/Projected FCF is ranked lower than
68% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.92 vs. BRKR: 2.80 )
Ranked among companies with meaningful Price/Projected FCF only.
BRKR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.9  Med: 2.07 Max: 11.13
Current: 2.8
0.9
11.13
Price/Median PS Value 1.39
BRKR's Price/Median PS Value is ranked lower than
81% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. BRKR: 1.39 )
Ranked among companies with meaningful Price/Median PS Value only.
BRKR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 1.02 Max: 16.87
Current: 1.39
0.34
16.87
Price/Graham Number 3.90
BRKR's Price/Graham Number is ranked lower than
74% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.53 vs. BRKR: 3.90 )
Ranked among companies with meaningful Price/Graham Number only.
BRKR' s Price/Graham Number Range Over the Past 10 Years
Min: 1.07  Med: 3.12 Max: 30.19
Current: 3.9
1.07
30.19
Earnings Yield (Greenblatt) (%) 3.34
BRKR's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BRKR: 3.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BRKR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 5.00 Max: 19.4
Current: 3.34
1.9
19.4
Forward Rate of Return (Yacktman) (%) -1.73
BRKR's Forward Rate of Return (Yacktman) (%) is ranked lower than
77% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. BRKR: -1.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BRKR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.6  Med: 7.70 Max: 1478.7
Current: -1.73
-5.6
1478.7

More Statistics

Revenue(Mil) $1654
EPS $ 0.39
Beta0.90
Short Percentage of Float5.23%
52-Week Range $15.78 - 25.23
Shares Outstanding(Mil)167.88

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 1,660 1,727
EPS($) 0.91 1.02
EPS without NRI($) 0.91 1.02

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:BKD.Germany,
Bruker Corp is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of customers in life science, pharmaceutical, biotechnological, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, and infrared and Raman molecular spectroscopy technologies. Company manufacture and distribute a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. It also design, manufacture and market high and low temperature superconducting materials and devices based on metallic low temperature superconductors. The Company is organized into four operating segments: the Bruker BioSpin Group, the Bruker CALID Group, the Bruker MAT Group, and Bruker Energy & Supercon Technologies division. The Bruker BioSpin Group combines the Bruker Magnetic Resonance and Preclinical Imaging divisions and designs, manufactures and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. The Bruker CALID Group combines the Bruker Life Sciences and Clinical, Bruker Chemical and Applied Markets, Bruker Detection and Bruker Optics divisions. It designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as Chemical, Biological, Radiological, Nuclear and Explosive detection products and instruments based on Raman molecular spectroscopy technologies. The Bruker MAT Group combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions and designs, manufactures and distributes spectroscopy and microscopy instruments for the analysis of composition and structure in material science and life science samples. The Bruker Energy & Supercon Technologies division develops and produces low temperature superconductor and high temperature superconductor materials for use in advanced magnet technology and energy applications as well as linear accelerators, accelerator cavities, insertion devices, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. Company maintains direct sales forces throughout North America, Europe, Japan, Asia Pacific and Australia. It also utilizes indirect sales channels to reach customers. It also has various international distributors, independent sales representatives, and various other representatives in parts of Asia, Latin America, and Eastern Europe. Company have broad an
» More Articles for BRKR

Headlines

Articles On GuruFocus.com
Mariko Gordon Nearly Doubles Stake in Forward Air Jan 04 2016 
Mariko Gordon Acquires Five New Stakes in Second Quarter Aug 27 2015 
Insiders New Buys: Bruker Corp Jun 22 2015 
Weekly CEO Buys Highlight: BRKR, GAIN, LUB, NUVA, FGP Jun 21 2015 
Weekly CEO Buys Highlight: NGL, BRKR, UTHR, KTOS, GBL Dec 24 2012 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 10,000 Shares Mar 17 2011 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 1,220 Shares Mar 03 2011 
Weekly CEO Buys Highlight: Deer Consumer Products, Dynex Capital, Bruker BioSciences Corp, American Mar 27 2010 
Weekly CEO Buys Highlight: Bruker BioSciences Corp, Dynex Capital Inc, American Dairy Inc, Pioneer D Mar 21 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 100,000 Shares Mar 18 2010 

More From Other Websites
Bruker Corp. Earnings Analysis: Q4, 2015 By the Numbers Feb 12 2016
Bruker Corp. breached its 50 day moving average in a Bullish Manner : February 12, 2016 Feb 12 2016
Bruker (BRKR) Looks Good: Stock Adds 7.6% in Session Feb 12 2016
Bruker (BRKR) Tops Q4 Earnings and Revenues; Margins Up Feb 11 2016
Technical Coverage on Medical Laboratories & Research Equities -- Bruker, Quest Diagnostics,... Feb 11 2016
Edited Transcript of BRKR earnings conference call or presentation 10-Feb-16 9:45pm GMT Feb 11 2016
Bruker tops Street 4Q forecasts Feb 10 2016
Bruker tops Street 4Q forecasts Feb 10 2016
BRUKER CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 10 2016
4:05 pm Bruker beats by $0.11, beats on revs; guides FY16 EPS in-line Feb 10 2016
Bruker Reports Fourth Quarter and Fiscal Year 2015 Financial Results Feb 10 2016
Q4 2015 Bruker Corp Earnings Release - After Market Close Feb 10 2016
Bruker Announces Date and Time of Fourth Quarter and Full Year 2015 Earnings Release and Webcast Feb 01 2016
Bruker Announces Date and Time of Fourth Quarter and Full Year 2015 Earnings Release and Webcast Feb 01 2016
Bruker Corp. – Value Analysis (NASDAQ:BRKR) : January 25, 2016 Jan 25 2016
Bruker (BRKR) Stock Upgraded at Cantor Fitzgerald Jan 25 2016
Bruker Corp. breached its 50 day moving average in a Bullish Manner : January 25, 2016 Jan 25 2016
Bruker upgraded by Cantor Fitzgerald Jan 25 2016
How to Pick Winning Stocks When the Market is Going Down Jan 20 2016
Bruker (BRKR) Looks Good on Strategic Initiatives: Invest Now Jan 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK